Endometrial cancer with no specific molecular profile

What changed: Endometrial cancer with no specific molecular profile

Cancer page →

Every dated change on the records linked to Endometrial cancer with no specific molecular profile, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.

Trial result6Milestone6This record1

FollowWatch this cancer and Saved shows what changed since you last looked.Follow by feed

September 2026 · 1

2026-09-17This recordEndometrial cancer with no specific molecular profile
Facts on this page last checked
When this page itself was last checked or edited.

2026 · 2

2023 · 2

2022 · 1

2022MilestoneEndometrial cancer with no specific molecular profile
RAINBO NSMP-ORANGE opens: progestin versus chemotherapy after surgery
A milestone in how this cancer is treated.

2021 · 2

2018 · 1

2018Trial resultPORTEC-3
PORTEC-3 reported
5-year OS 81.

2017 · 1

2017Trial resultFIRES & SENTOR (sentinel node mapping)
FIRES & SENTOR (sentinel node mapping) reported
Sensitivity 97%, NPV 99.

2013 · 1

2013MilestoneEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
TCGA defines the copy-number-low class
A milestone in how this cancer is treated.

2010 · 1

2010MilestoneBrachytherapy
PORTEC-2: vaginal brachytherapy replaces pelvic radiotherapy for high-intermediate risk
A milestone in how this cancer is treated.

1983 · 1

1983MilestoneEndometrial cancer with no specific molecular profile
Bokhman's type I oestrogen-driven endometrial cancer, the ancestor of this class
A milestone in how this cancer is treated.